aav2 cag flpo solution Search Results


94
Vector Biolabs aav2 cag flpo solution
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Aav2 Cag Flpo Solution, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/AAV-CAG-FLPo/pmc12929473-207-5-13
Average 94 stars, based on 1 article reviews
aav2 cag flpo solution - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

95
Addgene inc aav2 retro ef1a flpo
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Aav2 Retro Ef1a Flpo, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/pAAV-EF1a-Flpo+(Plasmid+%2355637)/bio_rxiv__2024__08__14__607871-159-31-32
Average 95 stars, based on 1 article reviews
aav2 retro ef1a flpo - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

86
Obio Technology Corp Ltd aav2 retro hsyn flpo
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Aav2 Retro Hsyn Flpo, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/particles+viral/pm39150998-281-0-14
Average 86 stars, based on 1 article reviews
aav2 retro hsyn flpo - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

94
Addgene inc aav2
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Aav2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/pAAV-hSynapsin-Flpo+(Plasmid+%2360663)/pmc07606600-215-14-22
Average 94 stars, based on 1 article reviews
aav2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
Addgene inc paav ef1a mcherry ires flpo
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Paav Ef1a Mcherry Ires Flpo, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/pAAV-EF1a-mCherry-IRES-Flpo+(Plasmid+%2355634)/pm40335692-581-5-6
Average 93 stars, based on 1 article reviews
paav ef1a mcherry ires flpo - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
Addgene inc aav1 aav2
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Aav1 Aav2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/AAV+pEF1a-DIO-FLPo-WPRE-hGHpA+(Plasmid+%2387306)/pm36610397-187-2-0
Average 94 stars, based on 1 article reviews
aav1 aav2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

95
Vector Biolabs flippase expressing cassette
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Flippase Expressing Cassette, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/AAV-eSYN-EGFP-T2A-FLPo/pmc08505251-47-9-13
Average 95 stars, based on 1 article reviews
flippase expressing cassette - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

96
Addgene inc aavrg aav2 retro helper hsyn flp off cre
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Aavrg Aav2 Retro Helper Hsyn Flp Off Cre, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/pAAV-hSyn-EGFP+(Plasmid+%2350465)/pm41118757-750-134-147
Average 96 stars, based on 1 article reviews
aavrg aav2 retro helper hsyn flp off cre - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

93
Addgene inc pennsylvania gene therapy program
Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce <t>CreER</t> <t>recombination.</t> <t>AAV2-CAG-FLPo</t> was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.
Pennsylvania Gene Therapy Program, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav2+cag+flpo+solution/pNN7+(Plasmid+%2331013)/pm34146468-277-14-34
Average 93 stars, based on 1 article reviews
pennsylvania gene therapy program - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce CreER recombination. AAV2-CAG-FLPo was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.

Journal: Frontiers in Neuroscience

Article Title: Differentiation timing-dependent axon targeting and subtype specification in retinal ganglion cells

doi: 10.3389/fnins.2026.1733811

Figure Lengend Snippet: Axon projections of the neurogenic-tagged RGCs in the optic tract and LGN. (A) Schematic gene structures of the neurogenic tagging driver Neurod1 CreER (D1B) and R26-CAG-LF-mTFP1 reporter. Tamoxifen (TM) injection was administered at E11.5, E13.5, or E15.5 to induce CreER recombination. AAV2-CAG-FLPo was injected intravitreally at the postnatal stage to induce Flp recombination in an eye-specific manner. (B,C) Labeling of TM-tagged axon arbors by mTFP1 immunostaining (white in the upper panels, green in the lower panels) in brain sections. The TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (B) Labeled axons in the contralateral optic tract (arrowheads) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. The dotted line indicates the optic tract border. (C) Labeled axons in the dorsal lateral geniculate nucleus (dLGN; arrowheads) and ventral LGN (vLGN; arrows) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Contra, contralateral projections; Ipsi, ipsilateral projections. Scale bars, 250 μm.

Article Snippet: One to two microliters of AAV2-CAG-FLPo solution (4.5 × 10 12 genome copies/ml; Vector Biolabs, Cat# VB1313) was injected through the hole using a pulled and beveled glass pipette (Drummond Cat#5–000-1001-X10).

Techniques: Injection, Labeling, Immunostaining, Staining

Axonal projections of the neurogenic-tagged RGCs in the MTN and SCN. (A,B) Labeling of TM-tagged axon arbors by mTFP1 staining (white in upper panels, green in lower panels) in brain sections using the same strategy as in : Neurod1 CreER (D1B) mice were crossed with R26-CAG-LF-mTFP1 reporter mice, followed by intravitreal injection of AAV2-CAG-FLPo into one eye at the postnatal stage. TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (A) Labeled axons in the contralateral medial terminal nucleus (MTN), indicated by arrowheads, at P29 for TM11.5, P35 for TM13.5, and P32 for TM15.5. MTNd, dorsal MTN; MTNv, ventral MTN. (B) Suprachiasmatic nucleus (SCN) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Right, contralateral side; left, ipsilateral side. The dotted line indicates the border of the SCN. Scale bars: 50 μm (A) and 250 μm (B) .

Journal: Frontiers in Neuroscience

Article Title: Differentiation timing-dependent axon targeting and subtype specification in retinal ganglion cells

doi: 10.3389/fnins.2026.1733811

Figure Lengend Snippet: Axonal projections of the neurogenic-tagged RGCs in the MTN and SCN. (A,B) Labeling of TM-tagged axon arbors by mTFP1 staining (white in upper panels, green in lower panels) in brain sections using the same strategy as in : Neurod1 CreER (D1B) mice were crossed with R26-CAG-LF-mTFP1 reporter mice, followed by intravitreal injection of AAV2-CAG-FLPo into one eye at the postnatal stage. TM-tagging stages are indicated at the top. DAPI staining is shown in blue. (A) Labeled axons in the contralateral medial terminal nucleus (MTN), indicated by arrowheads, at P29 for TM11.5, P35 for TM13.5, and P32 for TM15.5. MTNd, dorsal MTN; MTNv, ventral MTN. (B) Suprachiasmatic nucleus (SCN) at P28 for TM11.5, P29 for TM13.5, and P32 for TM15.5. Right, contralateral side; left, ipsilateral side. The dotted line indicates the border of the SCN. Scale bars: 50 μm (A) and 250 μm (B) .

Article Snippet: One to two microliters of AAV2-CAG-FLPo solution (4.5 × 10 12 genome copies/ml; Vector Biolabs, Cat# VB1313) was injected through the hole using a pulled and beveled glass pipette (Drummond Cat#5–000-1001-X10).

Techniques: Labeling, Staining, Injection

Axonal projections of the neurogenic-tagged RGCs in the SC. (A,B) TM-tagged axon arbors labeled by mTFP1 staining (white in left panels, green in right panels) in the superior colliculus (SC) using the same strategy as in : Neurod1 CreER (D1B) mice were crossed with R26-CAG-LF-mTFP1 reporter mice, followed by intravitreal injection of AAV2-CAG-FLPo into one eye at the postnatal stage. TM-tagging stages are indicated at the top. Brain sections were analyzed at P28 for TM11.5, P35 for TM13.5, and P32 for TM15.5. DAPI staining is shown in blue. Arrowheads indicate labeled axons in the ipsilateral SC. Arrows indicate labeled axons in the contralateral SC. Right, contralateral side; left, ipsilateral side. (A) Rostral SC, (B) Caudal SC. Scale bars, 500 μm.

Journal: Frontiers in Neuroscience

Article Title: Differentiation timing-dependent axon targeting and subtype specification in retinal ganglion cells

doi: 10.3389/fnins.2026.1733811

Figure Lengend Snippet: Axonal projections of the neurogenic-tagged RGCs in the SC. (A,B) TM-tagged axon arbors labeled by mTFP1 staining (white in left panels, green in right panels) in the superior colliculus (SC) using the same strategy as in : Neurod1 CreER (D1B) mice were crossed with R26-CAG-LF-mTFP1 reporter mice, followed by intravitreal injection of AAV2-CAG-FLPo into one eye at the postnatal stage. TM-tagging stages are indicated at the top. Brain sections were analyzed at P28 for TM11.5, P35 for TM13.5, and P32 for TM15.5. DAPI staining is shown in blue. Arrowheads indicate labeled axons in the ipsilateral SC. Arrows indicate labeled axons in the contralateral SC. Right, contralateral side; left, ipsilateral side. (A) Rostral SC, (B) Caudal SC. Scale bars, 500 μm.

Article Snippet: One to two microliters of AAV2-CAG-FLPo solution (4.5 × 10 12 genome copies/ml; Vector Biolabs, Cat# VB1313) was injected through the hole using a pulled and beveled glass pipette (Drummond Cat#5–000-1001-X10).

Techniques: Labeling, Staining, Injection